Dr. Vinay Prasad, a known critic of the pharmaceutical industry and FDA, has been appointed head of the FDA's vaccine and biotech program. This move, announced by FDA Commissioner Dr. Marty Makary, follows the resignation of Dr. Peter Marks after a conflict over vaccination safety concerns. Prasad, who has criticized the current FDA structure, raises alarms about increased scrutiny for vaccines under his leadership, especially given his history of doubting the FDA's efficacy in approving new therapies. The appointment signals potential shifts in regulatory philosophy during turbulent political times.
Prasad's appointment raises concerns about whether vaccines and other new therapies will face unnecessary scrutiny from regulators, deviating from a long-standing practice.
His previous comments suggest a belief that the FDA, as it stands, may be more harmful than helpful, implying a significant shift in regulatory approach.
Collection
[
|
...
]